Escolar Documentos
Profissional Documentos
Cultura Documentos
LEAD COMPOUND
CH3
H3C
CH3
CH3
Hydrophobic
pocket
CH3 Fit
CH3 Fit
Receptor 1
No Fit
Fit
CH3
CH3
Steric
block
Receptor 2
HO
OH
H
N
Adrenaline
CH3
HO
HOCH2
Salbutamol
Propranolol
(-Blocker)
OH
H
N
CH3
CH3
CH3
HO
CH3
H
O
OH
N
H
CH3
HBr
H
Drug
a) NaH
b) R"I
R
O
Drug
Ether
Me
Drug
OR
Ester
H
Drug
Drug
R
OH
OHDrug
R"I
Amine
Drug
VOC-CI
C
O
OR
H+
R"OH
Drug
C
O
O
C
Drug
R OH-
R"COCl
Drug
OH
Drug
Ester
O
C
Drug
R H+
NH
R"COCl
Drug
NH2
Drug
NH
Amide
NR2
Drug
Amide
OH
H+
Drug
NR2
HNR2
Drug
C
O
Strong
H-Bond
(increased
activity)
H
O
H
O
Binding
site
Y
para-substitution
Binding Region
(H-Bond)
Binding
site
Y
Meta-substitution
Binding Region
(for Y)
MeSO2NH
6
7
8
NR
NH2
NH2
..
NH2
O
O
Meta substitution:
Inductive electron withdrawing
effect
Para substitution
Electron withdrawing effect due to
resonance
Inductive effects leading to a
weaker base
DRUG
Unused
binding
region
DRUG
Drug
extension
RECEPTOR
Binding regions
Binding group
RECEPTOR
Extra
functional
group
Hydrophobic pocket
Vacant
CH3
O
Binding
site
EXTENSION
CH3
N
H
O
O
(I)
O
CO2
Binding
site
N
H
O
CO2
O(CHMe2)
P
CH3
Sarin
(nerve gas)
H3C
H3C
CH3
OEt
P
O
Ecothiopate
(medicine)
OEt
H3C
H3C
N
CH3
CH3
Acetylcholine
HN
HN
CH3
CH3
H
N
Viagra
CH3
N
CH3
HO
OH
H
N
OH
Propranolol
(-Blocker)
Adrenaline
H3C
HN
Histamine
CH3
CH3
HO
NH2
N
H
HN
S
N
CH3
H
N
HN
Cimetidine (Tagamet)
(Anti-ulcer)
Strong
interaction
Chain
extension
RECEPTOR
RECEPTOR
Binding regions
A&B
Binding groups
O
N
(CH2)n
H
HO
Binding
group
Binding
group
Hydrophobic regions
Binding regions
(CH2)n
N
H
O
CO2
Binding site
O2C
Ph
Binding site
O 2C
N
H
N
H
CO2
Two interactions
Carboxylate ion out of range
CO2
Ph
Three interactions
Increased binding
Ring variations
Rationale
Replace aromatic/heterocyclic rings with other
ring systems
Done for patent reasons
F
SO2CH3
SO2CH3
X
X
N
N
Core
scaffold
General structure
for NSAIDS
Br
SO2CH3
CF3
SO2CH3
Ring variations
Rationale
Sometimes results in improved properties
N
N
N
N
N
OH
OH
C
Cl
Cl
Structure I
(Antifungal agent)
Ring
variation
UK-46245
Improved selectivity
Ring variations
Example - Nevirapine (antiviral agent)
O
O
HN
HN
N
CO2tBu
Lead compound
Me
N
t
CO2 Bu
HN
Additional
binding group
Nevirapine
Ring variations
Example - Pronethalol (-blocker)
H
HO
OH
C
NHR
OH
Me
Me
HO
R = Me Adrenaline
R = H Noradrenaline
H
N
Pronethalol
NH
Me
OH
N
Et
N
H
OMe
EtO2S
H
OMe
EtO2S
Sultopride
N
Et
DU 122290
Simplification
Rationale
Lead compounds from natural sources are often
complex and difficult to synthesize
Simplifying the molecule makes the synthesis of
analogues easier, quicker and cheaper
Simpler structures may fit the binding site better
and increase activity
Simpler structures may be more selective and
less toxic if excess functional groups are removed
Simplification
Methods
Retain pharmacophore
Remove unnecessary functional groups
OH
HOOC
Ph
Cl
Drug
NHMe
OMe
OH
Ph
Drug
NHMe
Simplification
Methods
Remove excess rings
HO
HO
HO
CH3
H
HO
Morphine
Levorphanol
CH3
Me
Me
Metazocine
Excess ring
CH3
Simplification
Methods
Remove asymmetric centre
H
X
C
Chiral
drug
Asymmetric center
H
X
C
Chiral
drug
X
Y
Achiral
drug
Y
X
C
Y
Achiral
drug
Simplification
Methods
Simplify in stages to avoid oversimplification
CH3
H3 C
GLIPINE
OH
OH
OH
OH
OH
OH
OH
OH
OH
OH
CH3
CH3
CH3
CH3
CH3
Pharmacophore
Simplification
Example: procaine
Important binding groups retained
Unnecessary ester removed
Complex ring system removed
Me
N
Et 2NCH 2CH2
CO 2Me
O
C
O
O
COCAINE
PROCAINE
Pharmacophore
NH 2
Simplification
Disadvantages
Important binding groups retained
Oversimplification may result in decreased activity
and selectivity
Simpler molecules have more conformations
More likely to interact with more than one target
binding site
May result in increased side effects
Simplification
Oversimplification of opioids
C
MORPHINE
C
C
C
SIMPLIFICATION
Simplification
Oversimplification of opioids
C
LEVORPHANOL
C
C
C
SIMPLIFICATION
Simplification
Oversimplification of opioids
C
METAZOCINE
C
C
C
SIMPLIFICATION
Simplification
Oversimplification of opioids
C
C
C
C
OVERSIMPLIFICATION
Simplification
Oversimplification of opioids
C
TYRAMINE
C
C
C
OVERSIMPLIFICATION
Simplification
Oversimplification of opioids
C
AMPHETAMINE
C
C
C
OVERSIMPLIFICATION
Rigidification
Endogenous lead compounds are often simple
and flexible
Fit several targets due to different active
conformations
Results in side effects
Rigidification
Endogenous lead compounds are often simple
and flexible
Fit several targets due to different active
conformations
Results in side effects
single bond
rotation
Flexible
chain
Different conformations
Rigidification
Strategy
Rigidify molecule to limit conformations conformational restraint
Increases activity - more chance of desired active
conformation being present
Increases selectivity - less chance of undesired
active conformations
Disadvantage
Molecule is more complex and may be more
difficult to synthesise
Rigidification
H
NH2Me
O
NH2Me
Bond rotation
II
O 2C
H
O H
O
NH2Me
H
RECEPTOR 1
O 2C
O H
NH2Me
RECEPTOR 2
Rigidification
Methods - Introduce rings
Bonds within ring systems are locked and cannot
rotate freely
Test rigid structures to see which ones have
retained active conformation
Rotatable bonds
Fixed bonds
O
NHMe
NH2Me
H
Flexible messenger
Rigid messenger
Rigidification
Methods - Introduce rings
NHMe
H
N
X
CH3
NHMe X
X
Introducing
rings
X
X
NHMe
NMe
OH
OH
OH
Rigidification
Rotatable
bonds
HN
CH3
HN
CH3
Me
N
Rigidification
Methods - Introduce rigid functional groups
Flexible chain
'locked' bonds
O
C
NH
Rigidification
Example
CO2H
Important
binding
groups
NH2
HN
Inhibits
platelet
aggregation
N
H
N
O
Ar
NH2
HN
HN
CO2H
N
H
N
N
CH3
Rigid
Rigid
O
Ar
Analogues
Rigid
Ar
Rigidification
Example - Combretastatin (anticancer agent)
Rotatable
bond
Z-isomer
H3CO
H3CO
OCH3
OCH3
OH
OH
OCH3
Combretastatin A-4
More active
H3CO
H3CO
H3CO
H3CO
OCH3
OH
OCH3
Combretastatin
OH
OCH3
E-isomer
Less active
Rigidification
Methods - Steric Blockers
X
Introduce
steric block
CH3
steric block
Y
X
Introduce
steric block
Steric
clash
Unfavourable conformation
Y
X
CH3
Coplanarity allowed
CH3
steric
clash
CH3
Orthogonal rings
preferred
Rigidification
Methods - Steric Blockers
H
N
H
N
O
N
CF3
Serotonin
antagonist
OMe
Introduce
methyl group
CH3
Steric
clash
H
H
N
O
N
CH3
CF3
OMe
Orthogonal ring
H
N
O
N
CF3
OMe
Increase in activity
Active conformation retained
Rigidification
Methods - Steric Blockers
Steric clash
freerotation
CF3O2SO
(CH2)4
Me
H
H
N
O
CF3O2SO
(CH 2)4
H
N
O
D3 Antagonist
Inactive
(active conformation disallowed)